tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

NVCT Stock Latest News

Buy Rating for Nuvectis Pharma’s NXP900 Driven by Promising Efficacy and Development Progress
RatingsBuy Rating for Nuvectis Pharma’s NXP900 Driven by Promising Efficacy and Development Progress
5d ago
NVCT
Nuvectis Pharma Reports Progress in Oncology Drug Development
PremiumCompany Announcements
Nuvectis Pharma Reports Progress in Oncology Drug Development
18d ago
NVCT
Nuvectis Pharma reports Q3 EPS (44c), consensus (25c)
PremiumThe Fly
Nuvectis Pharma reports Q3 EPS (44c), consensus (25c)
19d ago
NVCT
Nuvectis Pharma reports Q3 net loss $7.5M vs $4.2M last year
PremiumThe Fly
Nuvectis Pharma reports Q3 net loss $7.5M vs $4.2M last year
19d ago
NVCT
Nuvectis Pharma’s Phase 1 Study of NXP900: A Potential Game-Changer in Cancer Treatment
PremiumCompany Announcements
Nuvectis Pharma’s Phase 1 Study of NXP900: A Potential Game-Changer in Cancer Treatment
27d ago
NVCT
Promising Safety and Efficacy of Nuvectis Pharma’s NXP900 Drives Buy Recommendation
PremiumRatingsPromising Safety and Efficacy of Nuvectis Pharma’s NXP900 Drives Buy Recommendation
27d ago
NVCT
Nuvectis Pharma provides highlights from NXP900 poster presentations
Premium
The Fly
Nuvectis Pharma provides highlights from NXP900 poster presentations
27d ago
NVCT
Nuvectis Pharma Appoints Juan Sanchez to Board
Premium
Company Announcements
Nuvectis Pharma Appoints Juan Sanchez to Board
2M ago
8K
NVCT
Nuvectis Pharma appoints Juan Sanchez to board of directors
PremiumThe Fly
Nuvectis Pharma appoints Juan Sanchez to board of directors
2M ago
NVCT
Nuvectis Pharma initiates NXP900 program
PremiumThe Fly
Nuvectis Pharma initiates NXP900 program
3M ago
NVCT
Nuvectis Pharma’s Strategic Focus on NXP900 and Positive Outlook Amidst Promising Developments
PremiumRatings
Nuvectis Pharma’s Strategic Focus on NXP900 and Positive Outlook Amidst Promising Developments
4M ago
NVCT
Nuvectis Pharma Reports Q2 2025 Financial Results and Progress
PremiumCompany Announcements
Nuvectis Pharma Reports Q2 2025 Financial Results and Progress
4M ago
NVCT
Nuvectis Pharma reports Q2 EPS (30c) vs. (26c) last year
PremiumThe FlyNuvectis Pharma reports Q2 EPS (30c) vs. (26c) last year
4M ago
NVCT
Strategic Pipeline Reprioritization and Promising Clinical Progress Drive Buy Rating for Nuvectis Pharma
Premium
Ratings
Strategic Pipeline Reprioritization and Promising Clinical Progress Drive Buy Rating for Nuvectis Pharma
4M ago
NVCT
Nuvectis Pharma price target lowered to $10 from $15 at H.C. Wainwright
Premium
The Fly
Nuvectis Pharma price target lowered to $10 from $15 at H.C. Wainwright
4M ago
NVCT
Strategic Focus on NXP900 Drives Buy Rating for Nuvectis Pharma
PremiumRatings
Strategic Focus on NXP900 Drives Buy Rating for Nuvectis Pharma
4M ago
NVCT
Nuvectis Pharma provides final clinical data update from NXP800 Phase 1b study
PremiumThe Fly
Nuvectis Pharma provides final clinical data update from NXP800 Phase 1b study
4M ago
NVCT
Promising Potential of NXP900 in Combination Therapy for Resistant Lung Cancer Justifies Buy Rating
PremiumRatings
Promising Potential of NXP900 in Combination Therapy for Resistant Lung Cancer Justifies Buy Rating
5M ago
NVCT
Promising Developments in Nuvectis Pharma’s NXP900 Boost Buy Rating
PremiumRatings
Promising Developments in Nuvectis Pharma’s NXP900 Boost Buy Rating
5M ago
NVCT
Nuvectis Pharma’s NXP900 shows positive drug interaction results in lung cancer
PremiumThe FlyNuvectis Pharma’s NXP900 shows positive drug interaction results in lung cancer
5M ago
NVCT
Nuvectis Pharma Approves Proposals at Annual Meeting
Premium
Company Announcements
Nuvectis Pharma Approves Proposals at Annual Meeting
5M ago
8K
NVCT
Nuvectis Pharma Launches New $60M Stock Offering Program
Premium
Company Announcements
Nuvectis Pharma Launches New $60M Stock Offering Program
7M ago
8K
NVCT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >